Stock Performance Review on Drug Delivery Industry -- Adamis Pharma, Alkermes, PetMed Express, and Valeant Pharma

Thursday, October 5, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 5, 2017 /PRNewswire/ --

If you want a Stock Review on ADMP, ALKS, PETS, or VRX then come over to and sign up for your free customized report. On Wednesday, the NASDAQ Composite ended the day at 6,534.63, up 0.04%; the Dow Jones Industrial Average edged 0.09% higher, to finish at 22,661.64; and the S&P
500 closed at 2,537.74, marginally gaining 0.12%. US markets saw five out of nine sectors finishing the day in green, 3 in red, and 1 in neutral territory. has initiated research reports on the following Drug Delivery stocks: Adamis Pharmaceuticals Corp. (NASDAQ: ADMP), Alkermes PLC (NASDAQ: ALKS), PetMed Express Inc. (NASDAQ: PETS), and Valeant Pharmaceuticals International Inc. (NYSE: VRX). Daily Stock Tracker published comprehensive and free research reports on these stocks today at:

Adamis Pharmaceuticals 

San Diego, California headquartered Adamis Pharmaceuticals Corp.'s stock finished Wednesday's session 0.48% higher at $5.20 with a total trading volume of 482,375 shares. The stock has gained 56.63% in the previous twelve months and 65.08% since the start of this year. Shares of the Company are trading above their 50-day and 200-day moving averages by 3.53% and 22.04%, respectively. Moreover, shares of Adamis Pharma, which develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the US, have a Relative Strength Index (RSI) of 51.03.

On October 04th, 2017, research firm B. Riley & Co. resumed its 'Buy' rating on the Company's stock, with a target price of $9.50 per share. ADMP complete research report is just a click away and free at:


Shares in Dublin, Ireland headquartered Alkermes PLC rose 0.86%, ending yesterday's session at $51.87 with a total trading volume of 346,573 shares. The stock has gained 12.39% over the past twelve months. The Company's shares are trading below their 50-day moving average by 0.03%. Moreover, shares of Alkermes, which researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide, have an RSI of 51.72.  The complimentary report on ALKS can be downloaded at:

PetMed Express 

On Wednesday, Delray Beach, Florida headquartered PetMed Express Inc.'s stock saw an increase of 1.01%, to close the day at $35.16. A total volume of 720,719 shares was traded. The Company's shares have advanced 71.85% over the last twelve months and 52.41% on an YTD basis. The stock is trading above its 200-day moving average by 14.77%. Additionally, shares of PetMed Express, which operates as a pet pharmacy in the US, have an RSI of 41.69. Sign up for your complimentary research report on PETS at:

Valeant Pharmaceuticals International 

Shares in Laval, Canada headquartered Valeant Pharmaceuticals International Inc. ended the day 0.14% higher at $14.38. A total volume of 6.56 million shares was traded. The stock has gained 9.77% in the last one month. The Company's shares are trading above their 200-day moving average by 5.24%. Furthermore, shares of Valeant Pharma, which operates as a pharmaceutical and medical device company worldwide, have an RSI of 52.31. Get free access to your research report on VRX at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store